English Archives - Page 16 of 20

ZICCUM AB accepted as member of NIIMBL – prestigious US biopharma innovation group

Swedish vaccine innovation company ZICCUM AB has been accepted as a member of NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals. NIIMBL drives innovation and uptake of new technologies within biopharmaceutical manufacturing in the US. Ziccum’s LaminarPace technology air-dries vaccines and biologics at ambient temperatures, producing stable, dry-powder vaccines requiring no Cold Chain for storage or transportation.

NIIMBL is a public-private partnership spanning government, the biopharma industry, academia, trade organisations and more. It is co-funded by the the US National Institute of Standards and Technology (NIST), the U.S. Department of Commerce and members. NIIMBL’s mission is accelerating the development and uptake of next-generation biopharmaceutical manufacturing technologies within the US.

Ziccum CEO Göran Conradson: “It is an honour to be accepted as a member of NIIMBL, especially as a foreign bio-research company. Right now, innovation in biopharmaceutical manufacturing has never been more urgent. It is a global priority for all of us. We look forward to being active, collaborative and responsible members.”

READ MORE

Read more about NIIMBL here.
Read more about LaminarPace here.
Ziccum’s plans for regional Fill and Finish plants here.
Ziccum technology preparing for pandemics and reducing vaccine waste here.

ZICCUM AB accepted as member of NIIMBL - prestigious US biopharma innovation group

ZICCUM welcomes new 3.5 BUSD vaccine initiative from CEPI with special focus on vaccine manufacturing

“We welcome CEPI’s new global initiative to prepare for future pandemics” says Ziccum CEO Göran Conradson, “and in particular its commitment to providing significant funding towards new manufacturing innovation to help scale-up vaccine production in LMIC settings. Covid-19 has been an urgent wakeup call for all of us. The time for action is now, dry powder thermostable vaccines have a crucial role to play.”

CEPI, the Coalition for Epidemic Preparedness Innovations, has launched an ambitious, global 5-year initiative to better prepare for pandemics and reduce or even eliminate future risk from them.

A strong focus within the new initiative, with up to 1.7 BUSD committed in spending, is the development of manufacturing innovation to help scale up the production of vaccines and other biological countermeasures in LMIC settings, a shared priority with Ziccum. “Our planned Fill and Finish Plants would enable regions to manufacture their own dry powder vaccines close to home,” Conradson says, “and these vaccines would need no Cold Chain to be stored or transported. Pandemics know no borders. Nor should the technology that can defeat them.”

Detailed plans drawn up for a dry powder Fill and Finish plant by Ziccum and modular manufacturing partner KeyPlants show that such a plant could produce up to 30 million vials of dry powder vaccines at an estimated 80% less energy use, 65% less OPEX cost and 50% less CAPEX cost than today's freeze-drying plants.

The CEPI initiative also highlights the need for strategic alliances and networks between key manufacturers and global researchers, industry, the public and private sectors and global health partners. Again, this is an approach which closely matches that of Ziccum: “We have always stressed the need for committed collaboration amongst stakeholders,” Conradson says. “As a small, entrepreneurial company we are not in a position to lead this, but all of us within the vaccine arena now recognize that pandemic preparedness is on a war footing – and innovation has always been key to winning wars. We call upon all stakeholders involved to work together cohesively and to include small entrepreneurial companies holding key technologies in the crucial fight we face.”

READ MORE

About CEPI’s new plan here.
Ziccum’s plans for regional Fill and Finish plants here.
Ziccum technology preparing for pandemics and reducing vaccine waste here.
Ziccum’s global partnership approach here.

ZICCUM welcomes new 3.5 BUSD vaccine initiative from CEPI with special focus on vaccine manufacturing

ZICCUM AB on global vaccine summit: “Fill and Finish focus welcome, now let’s really collaborate”

A major two-day summit of the world's top pharma and public health sector players has ended with strong agreement that scale-up of vaccine manufacturing is an urgent priority for 2021 and 2022. The summit held on 8-9 March 2021 and accompanying landscape analysis (Vaccinating the world) both highlight the need for increased collaboration and Fill and Finish capacity for vaccines.

The summit concluded that serious bottlenecks continue to challenge the goal of increasing vaccine supply from around 3.5 – 5.5 billion doses to the required 12 billion doses needed in 2021, with the CEO of CEPI (the Coalition for Epidemic Preparedness Initiatives), Richard Hatchett noting “increasing signs of strain within supply chains”.

The landscape analysis includes a frank picture of the lack of data and capacity available in Fill and Finish vaccine packaging plants: “the available capacity to meet the required vial-capacity for COVID-19 vaccines, and the potential repercussion for the production of other health products is currently largely unknown”.

Ziccum CEO Göran Conradson: “We welcome the new landscape analysis and in particular its acknowledgment of the need for increased capacity and data around Fill and Finish. All of us within the vaccine arena now recognize that pandemic preparedness is on a war footing – and innovation has always been key to winning wars. It is now time to include innovation in all its forms in our fight against pandemics. Our planned air-drying Fill and Finish plants can be a vital part of our arsenal. Pandemics know no borders. Nor should the technology that can defeat them.”

NEW COLLABORATION, ROLES AND REPONSIBILITIES
Whilst the summit stressed the need for increased collaboration amongst vaccine players, Conradson believes that smaller, more innovative players urgently need to be brought into today’s global, long-term programs: “We have always stressed how crucial inclusive collaboration is,” Conradson says. “We call on all stakeholders involved to work together to accept the necessary roles and responsibilities – and to include even small-scale innovators that hold key technologies that can help prepare for pandemics and achieve safe and sustainable vaccine coverage for children everywhere.”

READ MORE

Read about the Vaccine Summit here.
Read the Vaccine Summit Landscape Analysis Vaccinating the world here
Read Ziccum’s plans for regional Fill and Finish plants here.
Ziccum technology preparing for pandemics and reducing vaccine waste here.
Ziccum’s global partnership approach here.

ZICCUM AB on global vaccine summit: “Fill and Finish focus welcome, now let’s really collaborate”

ZICCUM AB feedback to EU: “Pandemic preparation demands innovation in vaccine formulation”

As part of Ziccum’s strategy of actively reaching out to global vaccine policymakers worldwide, Ziccum CEO Göran Conradson has submitted formal feedback to the EU’s consultation for the European Health Emergency Preparedness and Response Authority (HERA): “Dry powder thermostable vaccines can be manufactured locally and transported anywhere with no need of a Cold chain—they will be a crucial weapon in preparing for and ultimately defeating pandemics.”

Ebola, Zika, SARS, MERS–in recent years waves of epidemics have swept across countries and continents, all with the potential to tip over into pandemics. “It’s one of the most urgent threats we face, and we need to start preparing now,” says Göran Conradson “one reason the new EU HERA project to strengthen and speed up pandemic preparedness in Europe is so impressive is because it recognizes the serious gaps that COVID-19 has revealed in how we respond to pandemics. HERA is very much creating new solutions, from research to licensing to supply, because better pandemic preparation has to include innovation.

“Bill and Melinda Gates’ 2021 Annual Letter states that ’pandemic preparedness must be taken as seriously as we take the threat of war’. That’s true, and let’s remember – innovation has always been crucial to winning wars.”

The HERA Incubator – ramping up vaccine production in Europe
The HERA Incubator emergency program, launched in February 2021, is a core part of HERA. It is an intensive project to ensure that all Europeans have access to COVID-19 vaccines as soon as possible. It is focused on optimizing and speeding up research, development and production of new vaccines for new COVID-19 variants, across Europe. It explicitly identifies increasing industrial production, monitoring supply chains and solving production bottlenecks as key priority areas.

Ziccum is taking an increasingly proactive role in reaching out to European and global vaccine policy projects and makers. “As vaccine formulators we have to be involved in global policy – immunization is a cross-border endeavor by its very nature” Conradson says. “COVID-19 has reminded everyone, urgently, that there’s little point in one country gaining immunity if its next-door neighbor is still struggling with high infection rates. For us as a species, immunization is all or nothing. We’re all in it together.”

Ziccum has always stressed the importance of cross-industry partnerships and collaboration, Conradson points out. “HERA is just one of a wide range of collaborative cross-border, cross-industry initiatives from COVAX to GAVI working for more efficient and more equitable vaccine distribution.”

With the scale of the current pandemic, and the speed of new variants, Conradson says Ziccum is seeing growing awareness amongst many vaccine organizations that strengthening regional vaccine production and distribution needs to be an essential part of future preparedness and defeating new pandemics.

“Achieving global herd immunity could easily require developing and manufacturing billions of doses of vaccines worldwide a year,” he says. “Today’s top-down energy-intensive Cold Chain has already found it challenging coping with current demand. Will it be able to deliver the billions of vaccines required, frozen or chilled, across all continents and climate zones? It’s time to explore innovation in vaccine formulation. Our ambient air-drying technology can help regions manufacture robust, more easily transportable vaccines closer to home. That’s why we’re discussing establishing regional Fill and Finish plans, producing high volumes of thermostable vaccines, with policy makers across the world. Pandemics know no borders. Nor should the technology that can defeat them.”

READ MORE
·       Read Ziccum’s feedback to HERA here.
·       Ziccum’s plans for regional Fill and Finish plants here.
·       Ziccum technology preparing for pandemics and reducing vaccine waste here.
·       Ziccum’s global partnership approach here.

ZICCUM AB feedback to EU: “Pandemic preparation demands innovation in vaccine formulation”

ZICCUM AB Year-end report January 1- December 31, 2020

Summary of year-end report, fourth quarter 2020

During the fourth quarter, Ziccum announced that it had carried out a pilot study on large-scale production of temperature-stable vaccines. The pilot study centred on a Fill and Finish facility (the last step in vaccine production), with the aim of evaluating the technical and financial viability of commercial production of temperature-stable vaccines. The results of the study show that there are significant economic benefits to Ziccum's LaminarPace technology. The pilot study was carried out in collaboration with KeyPlants AB, a leading specialist company in modular plants for pharmaceutical production.

In collaboration with Keyplants AB, Ziccum has also published a White Paper and a blueprint describing the world's first Fill and Finish plant for large-scale production of temperature-stable vaccines. Compared with today's standard Fill and Finish plants with freeze-drying as the core technology, new thermostable vaccines can be produced with an estimated 65 percent lower OPEX, and 50 percent lower CAPEX.

On December 1, Ziccum made a list change to Nasdaq First North Growth Market.

Fourth quarter (Oct-Dec 2020)
Net sales 0 KSEK (0)
Operating profit -3 423 KSEK (-3 344)
Earnings per share before and after dilution -0.36 SEK (-0.56)

Reporting period (Jan-Dec) 2020
Net sales 0 KSEK (0)
Operating profit -17 235 KSEK (-8 721)
Earnings per share before and after dilution -2.06 SEK (-1.45)

Significant events during the fourth quarter 2020

Ziccum has carried out a pilot study into the large-scale production of thermostable vaccines in partnership with KeyPlants.
Ziccum has published a White Paper describing the world's first facility for large-scale production of thermostable vaccines.
On October 26, we announced that Frida Hjelmberg has been appointed CFO. Frida took office on January 1, 2021.
On December 1, Ziccum made a list change to Nasdaq First North Growth Market

Significant events during the reporting period (Jan-Dec) 2020

Issue receipts regarding warrants amounted to approximately SEK 13.9 million received to the company during January 2020. The issue was registered by the Swedish Companies Registration Office on 14 January 2020.
On March 26, 2020, we announced that Ziccum signed a letter of intent to investigate the integration of Ziccum's technology into an innovative vaccine manufacturing process with a company that has a new innovative production technology for vaccines. The agreement includes an evaluation of the integration of Ziccum's formulation technology for measles and rubella vaccines. The goal is to significantly reduce the costs of childhood vaccines and to increase the availability of vaccines to all children in the world by manufacturing thermostable formulations.
On May 20, we announced that Ziccum is taking the next step in one of its industrial collaborations with continued development work to formulate temperature-stable vaccines after the first step has been successful.
The company has completed a private placement of a total of 2,216,815 shares to a limited number of qualified private investors. The company received SEK 38.8 million before issue costs and approximately SEK 36.6 million after issue costs, of which approximately SEK 32.3 million received during the second quarter and the remaining approximately SEK 6.5 million received during July 2020.
A patent application has been filed regarding thermostable formulations of VLP (Virus Like Particles) based vaccines as well as two patent applications regarding improved function of the LaminarPace system for commercial vaccine production.

Significant events after the reporting period

On January 12, Ziccum released its corporate goals for 2021, the main goals being to enter into a first licensing agreement for one or more vaccines and to present a detailed plan to establish a Fill and finish production facility for the filling and final packaging of dry powder, thermostable vaccines including necessary partnerships and financing plans. In the medium term (2-3 years), the goal is to establish a first facility in Sweden.
On January 25, Ziccum announced that the company has extended the evaluation agreement that was concluded on October 3, 2019 with Janssen Vaccine & Prevention B.V., one of Janssen's pharmaceutical companies belonging to Johnson & Johnson. The purpose is to complete the analysis of Ziccum's air drying technology with Janssen's vaccine platforms.

Summary financial highlights

	2020 Oct-Dec	2019 Oct-Dec	2020 Jan-Dec	2019 Jan-Dec
Net sales	–	–	–	–
Other income, KSEK	3	–	5	654
Operating profit KSEK	-3 423	-3 344	-17 235	-8 721
Profit after tax, KSEK	-3 448	-3 346	-17 289	-8 723
Balance sheet total, KSEK	39 640	18 395	39 640	18 395
Cash flow during period KSEK	-5 941	-3 176	31 556	-8 473
Cash flow per share (SEK)	-0.62	-0.53	3.75	-1.41
Cash and cash equivalents, KSEK	33 620	2 064	33 620	2 064
Results per share before and after dilution (SEK)	-0.36	-0.56	-2.06	-1.45
Equity per share (SEK)	3.79	2.86	3.79	2.86
Equity ratio, %	92%	93%	92%	93%

CEO Statement
Vaccinations are and have always been one of the best ways to prevent pandemics and epidemics. The need has never been greater than today. New travel habits, population growth, climate change and overcrowding all increase the potential risk of epidemics and pandemics, and it is children who are most vulnerable: one child in five still does not receive adequate vaccination protection. Approximately 1.5 million children die each year from diseases for which vaccines are available.

Ziccum has a world-unique and patented technology – LaminarPace™ – which makes it possible to produce vaccines in dry powder form, which is neither practical nor economical using conventional techniques. The benefits are many. It increases the stability and thus the lifespan of the vaccine, it facilitates the entire transport chain from factory to patient and it enables the distribution of vaccines to new places where, for example, cold and freezer storage is a major challenge – vaccinating more people at a lower cost.

Ziccum's focus is described in three main areas. Development of thermostable formulations of vaccines, preparations for production on a commercial scale and external collaborations with industrial actors who develop vaccines and also, importantly for the industry, "non-governmental organizations".

Despite Covid-19, our internal work continues to develop thermostable formulations of vaccines. In collaboration with our academic partner, the world-leading university in viruses and vaccines in Marseille, several interesting and important projects are now underway. The results are promising and positively confirm what we have seen before, we will also strengthen our patent portfolio further with these results. A strong IP portfolio is the basis for being able to enter into commercial collaborations and create value for our shareholders.

We have two main goals for 2021, to develop plans for a Fill and Finish production facility for the filling and final packaging of vaccines to be established in Sweden, and to continue to license our technology. For the production facility, we are in discussion with a number of partners who are important in being able to carry out such a project. The goal of concluding a license agreement remains from the previous year. License revenues continue to be a central part of Ziccum's business model. A license agreement would validate LaminarPace and be a clear acknowledgment of the commercial value of Ziccum's offering. We signed an extension agreement with Janssen, owned by Johnsson & Johnsson, for further evaluation. This is following positive results that have been achieved so far.

Our external contacts are constantly being expanded and we are receiving an increasing response from the various players in the industry. Not least, our White Paper (available on our website) which broadly describes what a production facility based on our technology could look like has been much appreciated by important key players. We can see that we can make large cost savings in production in comparison with conventional freeze-drying technology.

Vaccines are a low-cost product in large parts of the world, which is why these results are so important. Now that we can describe a production facility, we have expanded our business model and added additional revenue opportunities, enabling us to have other types of discussion with both bulk vaccine suppliers and International Vaccine Organizations.

It also means that we can now work in a way that ensures that our technology can deliver an end product that is adapted to the needs and wishes of both the industry and, not least, end users. Our ambition is to be one step ahead, and able to offer a unique complete solution for how a dry-formulated vaccine can be produced, handled and administered. The capital we raised during the summer will largely be used for this business area, thus accelerating the commercialization of our technology. We have previously announced three industrial collaboration agreements with the aim of evaluating our technology in their respective projects.

We also continue to develop our commercial work by collaborating with various companies and groups that work for better uptake of vaccinations worldwide, in order to increase knowledge about the importance of our method. We are getting deeper and deeper into these organizations, and we have high hopes of being able to formalize a collaboration with one of these partners in the coming year.

In conclusion, we are well on our way towards delivering on our goals for the current year and to position Ziccum for a very exciting future within an industry that will continue to be focused on for a long time to come – finally, I would like to welcome all those new shareholders who have joined during the quarter, and to thank them for their trust and confidence.

Lund, 11 February 2021
Göran Conradson
CEO

READ THE WHOLE REPORT HERE

This press release has been submitted for publication by the company's CEO at 08.00 (CET) on February 11, 2021.

Bokslutskommuniké 2020 2021 02 09 08 17 35

Ziccum extends evaluation agreement with global pharmaceutical company

Lund, January 25, 2021 — Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive results from the initial phase of studying compatibility with a model vaccine technology platform, both companies have now extended the study agreement until June 30, 2021. This is to finalize the analysis of Ziccum’s air-drying capabilities on one of Janssen’s vaccine platform technologies.

“We’re very proud to extend this first pilot project with Janssen”, says Ziccum CEO Göran Conradson.

“The first pilot project collaboration turned out well”, Ziccum’s Chairman Fredrik Sjövall points out. “We are of course delighted that we are now extending this collaboration.”

LaminarPaceTM enables the air-drying of delicate biologic drugs such as proteins, peptides and vaccines at room temperature, keeping the active ingredient intact. This capability could enable the development of new, stable, dry powder formulations of vaccines and biologic therapies that can be transported and administered cost-effectively to any climate in the world. In this extended collaboration each party covers their own costs.

Ziccum extends evaluation agreement with global pharmaceutical company

Ziccum presents corporate goals for 2021

Lund, 12 January 2021. Ziccum's major goals for 2021 are to enter into its first licensing agreement for a dry-formulated vaccine, and to present a detailed plan for establishing a Fill and Finish production facility for the filling and final packaging of dry, thermostable vaccines based on Ziccum's unique technology.

The Board of Ziccum AB announces the release of its major goals and sub-goals for 2021. Its major goals for 2021 are:

• To enter into a first licensing agreement regarding one or more vaccines

• To present a detailed plan for establishing a modular Fill and Finish production facility for filling and final packaging of dry, thermostable powder vaccines, including the necessary partnerships and financing plans

Licensing agreement
The goal of concluding a licensing agreement remains from the previous year. License revenues continue to be a central part of Ziccum's business model. A licensing agreement would validate LaminarPace and be a clear endorsement of the commercial value of Ziccum's offering. Whilst Covid-19 has caused some delays in the Company's three ongoing collaborations, these projects have nevertheless continued to move forward and make progress.

Fill and Finish plant
Our goal in 2021 is to present a detailed plan for establishing a Fill and Finish production facility for filling and final packaging of dry, thermostable powder vaccines that will include the necessary partnerships and financing plan. In 2020, Ziccum carried out a concept study of a plan to produce a vaccine Fill and Finish production facility together with KeyPlants AB using their modular construction system. The study showed that Ziccum’s technology delivered several advantages over (traditional) freeze-drying technologies;

• 80% lower electricity demand
• 67% lower operating costs
• 50% lower investment costs

The concept study has been well received by the industry and a variety of actors within the vaccination arena. The establishing of a Fill and Finish facility would appreciably clarify Ziccum’s offering to both the vaccine industry and end users of vaccines. The company's business model and revenue opportunities would significantly expand through being able to take a larger part of the value chain. Ziccum’s medium term goal (2–3 years) is to establish a first Fill and Finish facility for dry-formulated vaccines in Sweden. This facility could then be duplicated, and a parallel one placed anywhere in the world. The urgent need for countries and / or regions to be able to take greater control over their own vaccine supply is currently being championed by organizations like UNIDO (United Nations Industrial Development Organization: www.unido.org), and others. They point out that this would enable the delivery of vaccine products better adapted to local needs, such as higher temperature-resistance, and help drive forward socio-economic development across regions.

The necessary prerequisites for establishing a Fill and Finish facility are that Ziccum:

• Receives significant external financing through grants, loan financing and / or other forms of alternative financing (not dilution of the share capital)

• Obtains approved bulk vaccines for reformulation using Ziccum's method. This means working closely with a vaccine manufacturer.

In addition, Ziccum intends to initiate cooperation with a country or region in order to be able to establish a parallel facility in the long-term to further increase the amount of vaccinations in areas in great need of temperature-stable vaccines.

Further goals and key activities

International collaborations
The vaccine market relies hugely on the work of organizations such as IGOs (International Governmental Organizations) and NGOs (Non-Governmental Organizations), who influence it in many ways, for example through purchasing and distributing vaccines. An example of an important IGO is UNICEF, which accounts for as much as 50 percent of the purchases of all childhood vaccines. A key success factor for Ziccum is to ensure that these organizations know and understand Ziccum's technology and how it can develop new dosage formulations that are less dependent on the cold chain. In this way, these organizations can set requirements and encourage established vaccine manufacturers to work for change to deliver temperature-stable formulations. Our goal is to formalize a collaboration with at least one of these organizations during 2021.

Patent
It is the Company's ambition to continue to set a high pace in its own Research and Development activities, with the aim of generating new data that can form the basis for further patent applications, primarily for more types of vaccines. As part of this, in 2021 we will continue our work with AMU, Aix-Marseille University, which has access to and extensive knowledge of a wide range of viruses and vaccines.

Process development
Ziccum attaches great importance to developing its formulation process for temperature-stable vaccines and adapting it for industrial production, with the goal of streamlining ongoing and upcoming collaborative discussions with industrial partners. This project includes increasing production capacity and automating the management of the system and processes, as well as adapting it to government-controlled vaccine production.

Grant applications
The vaccine market offers a number of opportunities to obtain different forms of grants. Ziccum will make applications for those grants that it deems to be relevant, obtainable and in in its interest.

Organizational development
Ziccum has gone from three employees in the beginning of 2020 to seven in the beginning of 2021. We will continue to need to employ competent and experienced staff to further strengthen our ability to deliver on our stated goals.

Corporate goals: These refer to set future objectives for Ziccum's business and operations. The company's operations and activities will steer towards these goals. Given future uncertainties however, it cannot be promised that the Company will be able to achieve these goals.

Ziccum presents corporate goals for 2021

Market Notice 280/20 – Ziccum AB will be delisted after close of the market on November 30, 2020

Ziccum AB will be delisted from Spotlight after close of the market on November 30, 2020. For more information, see the press release from the company.

Information about the share:
Shortname: ZICC
ISIN-code: SE0011415595
Orderbook-ID: 4NG9
CFI: ESVUFR
FISN: ZICCUM/SH
Organisation number: 559107-9412
LEI: 5493005TADJBZHXP0U27
Last day of trading at Spotlight: November 30, 2020

Stockholm November 16, 2020

Spotlight Stock Market
08-511 68?000
trading@spotlightstockmarket.com

Release

Ziccum AB carries out list change to Nasdaq First North Growth Market and releases company description

Ziccum AB ("Ziccum" or "the Company") announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market will be December 1, 2020.

Trading in the Company's share on the Spotlight Stock Market will cease and the last day for trading on the Spotlight Stock Market will be November 30, 2020.

Nasdaq's decision is subject to the condition that (i) nothing occurs in connection with the list change that could lead to a different assessment of the stock exchange, (ii) the Company meets the proliferation requirement in accordance with the Nasdaq First North Growth Market Rulebook and that (iii) the Company updates its website in in accordance with the Nasdaq First North Growth Market Rulebook.

The company's share will continue to be traded under the short name ZICC with its current ISIN code SE0011415595. No new shares will be issued in connection with the Company's shares being admitted to trading on the Nasdaq First North Growth Market. The Company's shareholders do not need to take any measures in connection with the list change.

Due to the listing on Nasdaq First North Growth Market, the Company has prepared a company description which is available on Ziccum's website (in Swedish) www.ziccum.com. Ziccum has appointed Erik Penser Bank as the Company's Certified Adviser. The company's legal advisor is Fredersen Advokatbyrå AB.

"The listing on Nasdaq First North Growth Market is a natural step in our ambition for a more international profile and entails better conditions for future value creation for Ziccum's shareholders. Nasdaq is a global and well-known brand that enables increased visibility in the stock market and makes it easier for institutional and international investors to become shareholders in the company." – CEO Göran Conradson.

For more information about Ziccum, please contact:

Göran Conradson:

CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00

Mail: certifiedadviser@penser.se

About Ziccum

Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.

This is a regulatory press release that was submitted for publication by the company's CEO at 12.30 CET on November 11, 2020.

Ziccum AB carries out list change to Nasdaq First North Growth Market

1 2 3 … 13 14 15 16 17 18 19 20

Posts navigation